Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1988 Nov 12;297(6658):1236–1239. doi: 10.1136/bmj.297.6658.1236

Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects.

J P Vora 1, D R Owens 1, J Dolben 1, J A Atiea 1, J D Dean 1, S Kang 1, A Burch 1, J Brange 1
PMCID: PMC1834710  PMID: 3145064

Abstract

OBJECTIVE--To compare the rate of absorption from subcutaneous tissue and the resulting hypoglycaemic effect of iodine-125 labelled soluble human insulin and a monomeric insulin analogue derived by recombinant DNA technology. DESIGN--Single blind randomised comparison of equimolar doses of 125I labelled soluble human insulin and insulin analogue. SETTING--Study in normal people at a diabetes research unit and a university department of medical physics. SUBJECTS--Seven healthy male volunteers aged 20-39 not receiving any other drugs. INTERVENTIONS--After an overnight fast and a basal period of one hour two doses (0.05 and 0.1 U/kg) of 125I labelled soluble human insulin and insulin analogue were injected subcutaneously into the anterior abdominal wall on four separate days. END POINT--To find a fast acting insulin for meal related requirements in insulin dependent diabetics. MEASUREMENTS and main results--Residual radioactivity at the injection site was measured continuously for the first two hours after injection of the 125I labelled preparations and thereafter for five minutes simultaneously with blood sampling. Frequent venous blood samples were obtained over six hours for determination of plasma immunoreactive insulin, insulin analogue, glucose, and glucagon values. Time to 50% of initial radioactivity at the injection site for the insulin analogue compared with soluble insulin was 61 v 135 minutes (p less than 0.05) with 0.05 U/kg and 67 v 145 minutes (p less than 0.001) with 0.1 U/kg. Concentrations in plasma increased faster after the insulin analogue compared with soluble insulin, resulting in higher plasma concentrations between 10 and 150 minutes (0.001 less than p less than 0.05) after 0.05 U/kg and between 40 and 360 minutes (0.001 less than p less than 0.05) after 0.1 U/kg. The hypoglycaemic response to insulin analogue was a plasma glucose nadir at 60 minutes with both doses compared with 90 and 120 minutes with soluble insulin at 0.5 and 0.1 U/kg respectively. The response of glucagon substantiated the earlier and more dramatic hypoglycaemic effect with the insulin analogue. CONCLUSIONS--The much faster absorption from subcutaneous tissue of the disubstituted monomeric insulin analogue compared with soluble insulin suggests that the analogue may be a potential candidate for rapid insulin delivery after subcutaneous bolus injection.

Full text

PDF
1236

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed M., Gannon M. C., Nuttall F. Q. Postprandial plasma glucose, insulin, glucagon and triglyceride responses to a standard diet in normal subjects. Diabetologia. 1976 Mar;12(1):61–67. doi: 10.1007/BF01221966. [DOI] [PubMed] [Google Scholar]
  2. Berger M., Cüppers H. J., Hegner H., Jörgens V., Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care. 1982 Mar-Apr;5(2):77–91. doi: 10.2337/diacare.5.2.77. [DOI] [PubMed] [Google Scholar]
  3. Brange J., Ribel U., Hansen J. F., Dodson G., Hansen M. T., Havelund S., Melberg S. G., Norris F., Norris K., Snel L. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988 Jun 16;333(6174):679–682. doi: 10.1038/333679a0. [DOI] [PubMed] [Google Scholar]
  4. Eaton R. P., Allen R. C., Schade D. S., Standefer J. C. "Normal" insulin secretion: the goal of artificial insulin delivery systems? Diabetes Care. 1980 Mar-Apr;3(2):270–273. [PubMed] [Google Scholar]
  5. Eaton R. P., Spencer W., Schade D. S., Shafer B. D., Corbett W. Diabetic glucose control: matching plasma insulin concentration to dietary and stress hyperglycemia. Diabetes Care. 1978 Jan-Feb;1(1):40–44. doi: 10.2337/diacare.1.1.40. [DOI] [PubMed] [Google Scholar]
  6. Edsberg B., Herly D., Hildebrandt P., Kühl C. Insulin bolus given by sprinkler needle: effect on absorption and glycaemic response to a meal. Br Med J (Clin Res Ed) 1987 May 30;294(6584):1373–1376. doi: 10.1136/bmj.294.6584.1373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Galloway J. A., Spradlin C. T., Nelson R. L., Wentworth S. M., Davidson J. A., Swarner J. L. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981 May-Jun;4(3):366–376. doi: 10.2337/diacare.4.3.366. [DOI] [PubMed] [Google Scholar]
  8. Genuth S. M. Plasma insulin and glucose profiles in normal, obese, and diabetic persons. Ann Intern Med. 1973 Dec;79(6):812–822. doi: 10.7326/0003-4819-79-6-812. [DOI] [PubMed] [Google Scholar]
  9. Hansen A. P., Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia. 1970 Feb;6(1):27–33. doi: 10.1007/BF00425888. [DOI] [PubMed] [Google Scholar]
  10. Heding L. G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia. 1972 Aug;8(4):260–266. doi: 10.1007/BF01225569. [DOI] [PubMed] [Google Scholar]
  11. Heding L. G. Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia. 1971 Feb;7(1):10–19. doi: 10.1007/BF02346248. [DOI] [PubMed] [Google Scholar]
  12. Hildebrandt P., Sejrsen P., Nielsen S. L., Birch K., Sestoft L. Diffusion and polymerization determines the insulin absorption from subcutaneous tissue in diabetic patients. Scand J Clin Lab Invest. 1985 Dec;45(8):685–690. doi: 10.1080/00365518509155280. [DOI] [PubMed] [Google Scholar]
  13. Jørgensen K. H., Larsen U. D. Homogeneous mono-(125)i-insulins. Preparation and characterization of mono-(125)i-(tyr a14)-and mono-(125)i-(tyr a19)-insulin. Diabetologia. 1980;19(6):546–554. doi: 10.1007/BF00253183. [DOI] [PubMed] [Google Scholar]
  14. Kinmonth A. L., Baum J. D. Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children. Br Med J. 1980 Mar 1;280(6214):604–606. doi: 10.1136/bmj.280.6214.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lean M. E., Ng L. L., Tennison B. R. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J (Clin Res Ed) 1985 Jan 12;290(6462):105–108. doi: 10.1136/bmj.290.6462.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Linde B. Dissociation of insulin absorption and blood flow during massage of a subcutaneous injection site. Diabetes Care. 1986 Nov-Dec;9(6):570–574. doi: 10.2337/diacare.9.6.570. [DOI] [PubMed] [Google Scholar]
  17. Pehling G. B., Gerich J. E. Comparison of plasma insulin profiles after subcutaneous administration of insulin by jet spray and conventional needle injection in patients with insulin-dependent diabetes mellitus. Mayo Clin Proc. 1984 Nov;59(11):751–754. doi: 10.1016/s0025-6196(12)65585-2. [DOI] [PubMed] [Google Scholar]
  18. Schade D. S., Eaton R. P., Spencer W. Normalization of plasma insulin profiles in diabetic subjects with programmed insulin delivery. Diabetes Care. 1980 Jan-Feb;3(1):9–14. doi: 10.2337/diacare.3.1.9. [DOI] [PubMed] [Google Scholar]
  19. Taylor R., Home P. D., Alberti K. G. Plasma free insulin profiles after administration of insulin by jet and conventional syringe injection. Diabetes Care. 1981 May-Jun;4(3):377–379. doi: 10.2337/diacare.4.3.377. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES